Skip to main content
Home

Search form

  • ABOUT US
    • ECFS Society Details
      • Society Information
      • Applications for Support
    • ECFS Membership
      • Membership Subscription
      • Membership Demographics
    • Other Information
      • Latest News
      • Job Opportunities
      • Grants and Programmes
      • Links
  • RESEARCH
    • ECFS Projects
      • ECFS Clinical Trials Network
      • ECFS Patient Registry
    • ECFS Working Groups
      • Diagnostic Network
      • Exercise
      • Neonatal Screening
      • Fungal Pathogens
      • Pulmonary Exacerbation
    • Special Projects
      • ECFS / CF Europe Post-Doctoral Research Fellowship
      • CFQ-R questionnaire and CF candidates for lung transplant
      • EU funded projects
      • MucoFong International Project
      • Complete CFTR gene mutation analysis in European patients with Cystic Fibrosis
    • Past Working Groups
      • Cystic Fibrosis Molecular and Cell Biology and Physiology Basic Science
      • ECFS Gene Modifier Working Group
      • ECFS Non Tuberculous Mycobacteria Working Group
  • CARE
    • ECFS Standards Of Care
    • ECFS Working Groups
      • Exercise
      • Diagnostic Network
      • Neonatal Screening
      • Mental Health
      • Fungal Pathogens
      • Pulmonary Exacerbation
      • Telehealth
    • Allied Health Professionals
      • ECFS Nursing Special interest Group
      • European CF Pharmacy Group
      • European Cystic Fibrosis Nutrition Group
      • European Psychosocial Special Interest Group
      • ECFS Physiotherapy Special Interest International Group
  • EDUCATION
  • CONFERENCES & EVENTS
    • European Cystic Fibrosis Conference
    • ECFS Basic Science Conference
    • Related events
    • Past ECFS conferences
  • PUBLICATIONS
    • About Publications
      • The Journal of Cystic Fibrosis
      • ECFS Newsletter
      • ECFS Book
      • ERS Monograph
    • Resources
      • Search All Resources
      • CF Research News
      • Consensus Reports
      • ECFS Guidelines
      • Free Access Articles
      • CF Literature
  • MEMBERSHIP
  • LOG IN

CFTR modulator

A serious consideration about the wise use of the new, highly efficient, very expensive, treatment for cystic fibrosis (Trikafta©/Kaftrio©)

  • Read more about A serious consideration about the wise use of the new, highly efficient, very expensive, treatment for cystic fibrosis (Trikafta©/Kaftrio©)

Worldwide Estimates of Cystic Fibrosis Diagnosis and Treatment Access

  • Read more about Worldwide Estimates of Cystic Fibrosis Diagnosis and Treatment Access

The effect of ETI (Trikafta™) on blood sugars in adults with cystic fibrosis

  • Read more about The effect of ETI (Trikafta™) on blood sugars in adults with cystic fibrosis

New perspectives on physical exercise training in adults and children with cystic fibrosis

  • Read more about New perspectives on physical exercise training in adults and children with cystic fibrosis

Orkambi may improve liver disease in people with CF

  • Read more about Orkambi may improve liver disease in people with CF

Drug-Induced Liver Injury from Elexacaftor/Ivacaftor/Tezacaftor

  • Read more about Drug-Induced Liver Injury from Elexacaftor/Ivacaftor/Tezacaftor

Infant with cystic fibrosis has normal pancreas function and was missed by newborn screening after mom stayed on CFTR modulator therapy during pregnancy.

  • Read more about Infant with cystic fibrosis has normal pancreas function and was missed by newborn screening after mom stayed on CFTR modulator therapy during pregnancy.

Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC Study

  • Read more about Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC Study

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

  • Read more about Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

Accumulation and persistence of Ivacaftor in airway epithelia with prolonged treatment

  • Read more about Accumulation and persistence of Ivacaftor in airway epithelia with prolonged treatment
  • first
  • previous
  • 1
  • 2
  • 3
  • next
  • last
Terms & Conditions Privacy policy  Accessibility Sitemap Contact 
© EUROPEAN CYSTIC FIBROSIS SOCIETY 2025. All rights reserved. Website by VidaVia (link is external)
European Cystic Fibrosis Society (ECFS)